<p>Veracyte, Inc.（纳斯达克代码：VCYT - 获取免费报告）在周五的午盘交易中，股价下跌了 4.5%，原因是内部人士出售了该公司的股票。该公司股价最低曾达到 45.81 美元，最后交易价格为 45.2750 美元。在交易中，共成交 61,820 股，较平均交易量 1,098,376 股下降了 94%。该股票此前收盘价为 47.41 美元。</p>
<p>具体来说，内部人士 John Leite 在 12 月 4 日（星期四）出售了 1,278 股公司的股票，交易价格为每股平均 47.51 美元，总交易额为 60,717.78 美元。交易后，该内部人士持有 82,113 股公司股票，价值为 3,901,188.63 美元。这次交易使其持股比例减少了 1.53%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，首席执行官 Marc Stapley 在 12 月 4 日（星期四）出售了 7,668 股公司的股票，交易价格为每股平均 47.09 美元，总交易额为 361,086.12 美元。交易完成后，首席执行官持有 318,603 股公司股票，价值约为 15,003,015.27 美元。这代表其持股比例减少了 2.35%。该出售的披露信息可在 SEC 备案中找到。在其他消息中，首席财务官 Rebecca Chambers 在 12 月 4 日（星期四）出售了 13,278 股股票，交易价格为每股平均 46.84 美元，总交易额为 621,941.52 美元。出售后，首席财务官持有 109,496 股公司股票，价值为 5,128,792.64 美元。这代表其持股比例减少了 10.81%。该交易在 SEC 备案中披露，相关信息可通过 SEC 网站获取。</p>
<h2>分析师评级升级与降级</h2>
<p>几家研究公司最近对 VCYT 进行了评估。Weiss Ratings 在周一的研究报告中重申了对 Veracyte 股票的 “持有（c）” 评级。Guggenheim 在 11 月 5 日的报告中将 Veracyte 的目标价格从 40.00 美元上调至 45.00 美元，并给予该公司 “买入” 评级。Needham &amp; Company LLC 在 11 月 5 日的研究报告中将 Veracyte 的目标价格从 41.00 美元上调至 44.00 美元，并给予该股票 “买入” 评级。摩根士丹利在周一的研究报告中将 Veracyte 的目标价格从 40.00 美元上调至 48.00 美元，并给予该公司 “减持” 评级。最后，瑞银集团在 11 月 5 日的研究报告中将 Veracyte 的目标价格从 42.00 美元上调至 48.00 美元，并给予该公司 “买入” 评级。一位股票研究分析师对该股票给予了强烈买入评级，五位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 45.43 美元。</p>
<p><strong>查看我们对 Veracyte 的最新分析</strong></p>
<h2>Veracyte 股票表现</h2>
<p>该股票的 50 日移动平均线为 39.11 美元，200 日移动平均线为 31.88 美元。该公司的市值为 35.8 亿美元，市盈率为 119.45，贝塔值为 1.83。</p>
<p>Veracyte（纳斯达克代码：VCYT - 获取免费报告）最近一次发布财报是在 11 月 4 日（星期二）。该生物技术公司报告本季度每股收益为 0.51 美元，超出市场共识预期的 0.32 美元，超出幅度为 0.19 美元。该公司本季度的收入为 1.3187 亿美元，而市场共识预期为 1.2462 亿美元。Veracyte 的股本回报率为 7.23%，净利润率为 6.12%。该公司本季度的收入较去年同期增长了 13.8%。去年同期，该公司每股收益为 0.33 美元。整体来看，股票分析师预计 Veracyte, Inc.在当前财年将发布 0.68 美元的每股收益。</p>
<h2>对 Veracyte 的对冲基金看法</h2>
<p>对冲基金最近增加或减少了对该股票的持仓。BNP PARIBAS ASSET MANAGEMENT Holding S.A.在第二季度购买了 Veracyte 的新头寸，价值约为 25,000 美元。First Horizon Corp 在第三季度购买了 Veracyte 的新头寸，价值约为 31,000 美元。Osaic Holdings Inc.在第二季度将其在 Veracyte 的持股增加了 289.9%。Osaic Holdings Inc.现在持有 1,201 股该生物技术公司的股票，价值 33,000 美元，此前在上个季度又购买了 893 股。Headlands Technologies LLC 在第一季度购买了 Veracyte 的新头寸，价值 48,000 美元。最后，Neo Ivy Capital Management 在第三季度购买了 Veracyte 的新头寸，价值 56,000 美元。</p>
<h2>Veracyte 公司简介</h2>
<p>（获取免费报告）</p>
<p>Veracyte, Inc.从事诊断产品的研究、开发和商业化。该公司的产品组合包括 Afirma、Percepta 和 Envisia。其目标是治疗甲状腺癌、改善肺癌筛查以及明确特发性肺纤维化的诊断。该公司由 Bonnie H.创立。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Veracyte</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>Salesforce 股票如弹簧般蓄势待发，准备反弹</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>Marvell 的反弹延续：数据中心和 AMZN 芯片推动股价上涨</li>
<li>如何一步一步购买便宜股票</li>
<li>Ross Stores 股票能否在圣诞节前达到 200 美元？分析师认为有三个理由支持这一观点</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Veracyte 吗？</h2>
<p>在考虑 Veracyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Veracyte 并不在名单上。</p>
<p>虽然 Veracyte 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

VCYT

<p>Veracyte 的股票在关键高管，包括首席执行官 Marc Stapley 和首席财务官 Rebecca Chambers 的内部出售后下跌了 4.5%。该股票交易最低价为 45.81 美元，交易量显著下降。分析师对该股票的评级不一，普遍持中性买入意见，平均目标价为 45.43 美元。最近的财报超出预期，收入同比增长了 13.8%</p>

<p>Veracyte, Inc. (NASDAQ:VCYT - Get Free Report)'s stock price fell 4.5% during mid-day trading on Friday after an insider sold shares in the company. The company traded as low as $45.81 and last traded at $45.2750. 61,820 shares traded hands during trading, a decline of 94% from the average session volume of 1,098,376 shares. The stock had previously closed at $47.41.</p>
<div class="lb-trans"><p>Veracyte, Inc.（纳斯达克代码：VCYT - 获取免费报告）在周五的午盘交易中，股价下跌了 4.5%，原因是内部人士出售了该公司的股票。该公司股价最低曾达到 45.81 美元，最后交易价格为 45.2750 美元。在交易中，共成交 61,820 股，较平均交易量 1,098,376 股下降了 94%。该股票此前收盘价为 47.41 美元。</p>
</div><p>Specifically, insider John Leite sold 1,278 shares of the business's stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $47.51, for a total transaction of $60,717.78. Following the transaction, the insider owned 82,113 shares in the company, valued at $3,901,188.63. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, CEO Marc Stapley sold 7,668 shares of the company's stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $47.09, for a total transaction of $361,086.12. Following the completion of the transaction, the chief executive officer owned 318,603 shares in the company, valued at approximately $15,003,015.27. This represents a 2.35% decrease in their position. The disclosure for this sale is available in the SEC filing. In other news, CFO Rebecca Chambers sold 13,278 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $46.84, for a total transaction of $621,941.52. Following the sale, the chief financial officer owned 109,496 shares in the company, valued at $5,128,792.64. This represents a 10.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>具体来说，内部人士 John Leite 在 12 月 4 日（星期四）出售了 1,278 股公司的股票，交易价格为每股平均 47.51 美元，总交易额为 60,717.78 美元。交易后，该内部人士持有 82,113 股公司股票，价值为 3,901,188.63 美元。这次交易使其持股比例减少了 1.53%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，首席执行官 Marc Stapley 在 12 月 4 日（星期四）出售了 7,668 股公司的股票，交易价格为每股平均 47.09 美元，总交易额为 361,086.12 美元。交易完成后，首席执行官持有 318,603 股公司股票，价值约为 15,003,015.27 美元。这代表其持股比例减少了 2.35%。该出售的披露信息可在 SEC 备案中找到。在其他消息中，首席财务官 Rebecca Chambers 在 12 月 4 日（星期四）出售了 13,278 股股票，交易价格为每股平均 46.84 美元，总交易额为 621,941.52 美元。出售后，首席财务官持有 109,496 股公司股票，价值为 5,128,792.64 美元。这代表其持股比例减少了 10.81%。该交易在 SEC 备案中披露，相关信息可通过 SEC 网站获取。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>Several research firms have recently weighed in on VCYT. Weiss Ratings restated a &#34;hold (c)&#34; rating on shares of Veracyte in a research note on Monday. Guggenheim increased their price objective on shares of Veracyte from $40.00 to $45.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, November 5th. Needham &amp; Company LLC boosted their target price on Veracyte from $41.00 to $44.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, November 5th. Morgan Stanley increased their price objective on shares of Veracyte from $40.00 to $48.00 and gave the company an &#34;underweight&#34; rating in a research report on Monday. Finally, UBS Group boosted their target price on Veracyte from $42.00 to $48.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $45.43.</p>
<div class="lb-trans"><p>几家研究公司最近对 VCYT 进行了评估。Weiss Ratings 在周一的研究报告中重申了对 Veracyte 股票的 “持有（c）” 评级。Guggenheim 在 11 月 5 日的报告中将 Veracyte 的目标价格从 40.00 美元上调至 45.00 美元，并给予该公司 “买入” 评级。Needham &amp; Company LLC 在 11 月 5 日的研究报告中将 Veracyte 的目标价格从 41.00 美元上调至 44.00 美元，并给予该股票 “买入” 评级。摩根士丹利在周一的研究报告中将 Veracyte 的目标价格从 40.00 美元上调至 48.00 美元，并给予该公司 “减持” 评级。最后，瑞银集团在 11 月 5 日的研究报告中将 Veracyte 的目标价格从 42.00 美元上调至 48.00 美元，并给予该公司 “买入” 评级。一位股票研究分析师对该股票给予了强烈买入评级，五位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 45.43 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Veracyte</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Veracyte 的最新分析</strong></p>
</div><h2>Veracyte Stock Performance</h2>
<div class="lb-trans"><h2>Veracyte 股票表现</h2>
</div><p>The stock has a fifty day moving average of $39.11 and a 200-day moving average of $31.88. The company has a market cap of $3.58 billion, a PE ratio of 119.45 and a beta of 1.83.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均线为 39.11 美元，200 日移动平均线为 31.88 美元。该公司的市值为 35.8 亿美元，市盈率为 119.45，贝塔值为 1.83。</p>
</div><p>Veracyte (NASDAQ:VCYT - Get Free Report) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.19. The business had revenue of $131.87 million during the quarter, compared to the consensus estimate of $124.62 million. Veracyte had a return on equity of 7.23% and a net margin of 6.12%.The business's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the company earned $0.33 earnings per share. As a group, equities analysts anticipate that Veracyte, Inc. will post 0.68 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Veracyte（纳斯达克代码：VCYT - 获取免费报告）最近一次发布财报是在 11 月 4 日（星期二）。该生物技术公司报告本季度每股收益为 0.51 美元，超出市场共识预期的 0.32 美元，超出幅度为 0.19 美元。该公司本季度的收入为 1.3187 亿美元，而市场共识预期为 1.2462 亿美元。Veracyte 的股本回报率为 7.23%，净利润率为 6.12%。该公司本季度的收入较去年同期增长了 13.8%。去年同期，该公司每股收益为 0.33 美元。整体来看，股票分析师预计 Veracyte, Inc.在当前财年将发布 0.68 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Veracyte</h2>
<div class="lb-trans"><h2>对 Veracyte 的对冲基金看法</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Veracyte during the second quarter worth approximately $25,000. First Horizon Corp bought a new position in Veracyte in the third quarter worth approximately $31,000. Osaic Holdings Inc. grew its stake in Veracyte by 289.9% in the second quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 893 shares in the last quarter. Headlands Technologies LLC purchased a new position in Veracyte during the 1st quarter worth $48,000. Finally, Neo Ivy Capital Management bought a new stake in Veracyte during the 3rd quarter valued at $56,000.</p>
<div class="lb-trans"><p>对冲基金最近增加或减少了对该股票的持仓。BNP PARIBAS ASSET MANAGEMENT Holding S.A.在第二季度购买了 Veracyte 的新头寸，价值约为 25,000 美元。First Horizon Corp 在第三季度购买了 Veracyte 的新头寸，价值约为 31,000 美元。Osaic Holdings Inc.在第二季度将其在 Veracyte 的持股增加了 289.9%。Osaic Holdings Inc.现在持有 1,201 股该生物技术公司的股票，价值 33,000 美元，此前在上个季度又购买了 893 股。Headlands Technologies LLC 在第一季度购买了 Veracyte 的新头寸，价值 48,000 美元。最后，Neo Ivy Capital Management 在第三季度购买了 Veracyte 的新头寸，价值 56,000 美元。</p>
</div><h2>Veracyte Company Profile</h2>
<div class="lb-trans"><h2>Veracyte 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.</p>
<div class="lb-trans"><p>Veracyte, Inc.从事诊断产品的研究、开发和商业化。该公司的产品组合包括 Afirma、Percepta 和 Envisia。其目标是治疗甲状腺癌、改善肺癌筛查以及明确特发性肺纤维化的诊断。该公司由 Bonnie H.创立。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Veracyte</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>Marvell's Rally Extends: Data Centers and AMZN Chips Boost Shares</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>Could Ross Stores Stock Hit $200 by Christmas? Here Are 3 Reasons Analysts Think So</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Veracyte</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>Salesforce 股票如弹簧般蓄势待发，准备反弹</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>Marvell 的反弹延续：数据中心和 AMZN 芯片推动股价上涨</li>
<li>如何一步一步购买便宜股票</li>
<li>Ross Stores 股票能否在圣诞节前达到 200 美元？分析师认为有三个理由支持这一观点</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Veracyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Veracyte 吗？</h2>
</div><p>Before you consider Veracyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Veracyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Veracyte 并不在名单上。</p>
</div><p>While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Veracyte 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Veracyte（NASDAQ:VCYT）股价因内部人士出售股票下跌 4.5%